BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21839414)

  • 1. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
    Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
    Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
    J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
    Ohsumi S; Shimozuma K; Ohashi Y; Takeuchi A; Suemasu K; Kuranami M; Ohno S; Watanabe T
    Oncology; 2012; 82(3):131-8. PubMed ID: 22433221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer.
    Roy C; Choudhury KB; Pal M; Saha A; Bag S; Banerjee C
    Indian J Cancer; 2012; 49(3):266-71. PubMed ID: 23238142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of health state in patients with tinnitus: a comparison of the EQ-5D and HUI mark III.
    Maes IH; Joore MA; Cima RF; Vlaeyen JW; Anteunis LJ
    Ear Hear; 2011; 32(4):428-35. PubMed ID: 21221004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
    Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
    J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
    McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
    J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
    Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Doihara H; Akabane H; Kashiwaba M; Watanabe T; Ohashi Y; Mukai H
    Qual Life Res; 2017 Feb; 26(2):445-453. PubMed ID: 27517267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
    Pal SK; Childs BH; Pegram M
    Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
    Liang XF; Ma DC; Ding ZY; Liu ZZ; Guo F; Liu L; Yu HY; Han YL; Xie XD
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):764-8. PubMed ID: 24378099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.